{
    "Trade/Device Name(s)": [
        "Control-IQ+ technology"
    ],
    "Submitter Information": "Tandem Diabetes Care, Inc.",
    "510(k) Number": "K243823",
    "Predicate Device Reference 510(k) Number(s)": [
        "K232382"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QJI"
    ],
    "Summary Letter Date": "December 12, 2024",
    "Summary Letter Received Date": "December 12, 2024",
    "Submission Date": "December 12, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1356"
    ],
    "Regulation Name(s)": [
        "Interoperable Automated Glycemic Controller"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose",
        "Insulin"
    ],
    "Specimen Type(s)": [],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Alternate controller enabled (ACE) insulin pumps",
        "Compatible integrated continuous glucose monitors (iCGM)"
    ],
    "Method(s)/Technology(ies)": [
        "Automated glycemic control algorithm",
        "Integrated software",
        "Closed-loop insulin delivery"
    ],
    "Methodologies": [
        "Automated glycemic controller",
        "Software-based insulin delivery management"
    ],
    "Submission Type(s)": [
        "Software",
        "Accessory",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for Control-IQ+ technology software intended for automated insulin delivery in compatible ACE pumps based on iCGM readings and user inputs",
    "Indications for Use Summary": "Intended for use with compatible integrated continuous glucose monitors and ACE pumps to automatically adjust basal insulin delivery and provide correction boluses for management of Type 1 diabetes in persons 2+ years and Type 2 diabetes in persons 18+ years; for single patient use and requires prescription",
    "fda_folder": "Clinical Chemistry"
}